Northern Trust
ESLA icon

Northern Trust’s Estrella Immunopharma ESLA Stock Holding History

Northern Trust’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20.8K Hold
19,624
– – ﹤0.01% 4335
2025
Q4 		$30.6K Buy
+19,624
New +$37.1K ﹤0.01% 4351

Other funds holding ESLA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust's ESLA Position: Q1 2026 in Review

Northern Trust held its Estrella Immunopharma (ESLA) position steady in Q1 2026 at 19,624 shares worth $20.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4335.

Northern Trust first reported a position in ESLA in Q4 2025 and has held it in 2 quarters since. The position peaked at $30.6K in Q4 2025. 16 funds tracked by Wall St. Rank hold ESLA as of Q1 2026.

  • Northern Trust held 19,624 shares of Estrella Immunopharma worth $20.8K as of Q1 2026.
  • Northern Trust left its Estrella Immunopharma share count unchanged in Q1 2026.
  • Estrella Immunopharma made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4335 holding.
  • Northern Trust first reported a position in Estrella Immunopharma in Q4 2025 and has held it in 2 quarters since.
  • Northern Trust's Estrella Immunopharma position peaked at $30.6K in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.